Bayer AG BAYN StarRatingValueLabel_5Damien Conover, CFA - Sector Director - Morningstar Inc.

Last Price
27.40
Day Change
0.50|1.88%

As of 26/04/2024
17:39:04 CEST | EUR  Minimum 15 Minutes Delay.

Bid/OfferDay RangeVolume90d Ave VolMkt Cap
27.40 - 27.4826.97 - 27.584,690,2784,721,89826.42Bil
Last Close52 Week RangeP/EYield %ISIN
26.9024.96 - 60.3128.418.89DE000BAY0017

Bayer AG Share Price

Morningstar's Take BAYN

Largely on the basis of the strong competitive advantages of the healthcare group and to a lesser extent the crop science business, we believe Bayer has created a narrow economic moat. Bayer is evaluating the divestitures of the crop science and consumer healthcare businesses, which appear to hold few synergies with the prescription drug business.

Fair Value Estimate

68.00 EUR

Uncertainty

+ Avg

Economic Moat

Narrow

Financial Strength

Financial Strength
There is no one analyst in which a Quantitative Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.’s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here.
Damien Conover, CFA - Sector Director - Morningstar Inc.
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Financials
202120222023
more...
Income Statement
Revenue44,081.0050,739.0047,637.00
Operating Income6,909.007,333.008,036.00
Net Income1,000.004,150.00-2,941.00
Basic EPS1.024.22-2.99
Avg. Diluted Shares Outstanding982982982
Balance Sheet
Current Assets32,578.0037,760.0037,556.00
Non Current Assets87,663.0087,117.0078,703.00
Total Assets120,241.00124,877.00116,259.00
Current Liabilities29,403.0035,084.0029,457.00
Total Liabilities---
Total Equity33,020.0038,773.0032,927.00
Cash Flow
Operating Cash Flow5,089.007,093.005,117.00
Capital Expenditure-2,611.00-2,949.00-2,751.00
Free Cash Flow2,478.004,144.002,366.00

In millions, except "Basic EPS". Currency is EUR.

Company Profile

Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

Sector

Healthcare

Industry

Drug Manufacturers - General

Stock Style

Large-Value

Fiscal Year Ends

December

Employees

99,723
Key Stats
more...
Price/Earning TTM-8.99
Price/Book0.80
Price/Sales TTM0.55
Rev Growth (3 year avg)4.79
EPS Growth (3 year avg)-
Operating Margin % TTM16.87
Net Margin % TTM-6.17
ROE TTM-8.20
Debt/Equity1.16
Dividends
PreviousLatest
Declared Date02/03/2302/02/24
Ex-Div02/05/2329/04/24
Paid04/05/2302/05/24
Amnt2.400.11
Damien Conover, CFA - Sector Director - Morningstar Inc.
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures